- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
vaccines Animal biotechnology BIO biotechnology patent innovation BIOTECH economy biotech industry NIH United States Patent and Trademark Office FDA Technology Transfer Intellectual Property drug development economic development BIO International Convention 2012 BIO International Convention Patent Reform USPTOAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Public Policy
Category Archives: Public Policy
Latest From Public Policy
American Invents Act Strategies Highlighted at the IPCC Conference
By David Saravitz, Alston + Bird Day 2 of the 2012 BIO Intellectual Property Counsels’ Committee (IPCC) Spring Conference kicked off with a panel on the America Invents Act (AIA). The panel focused on how practitioners and the U.S. Patent & Trademark Office (USPTO) are dealing with various provisions of this new patent act. Mr. Ira Finkelstein, Senior Patent Counsel with Baxter Healthcare, led off the session initially discussing the first-inventor-to-file provision of the AIA (§ Read More >
Biotech Patent Case Law Updates at the IPCC
By John W. Cox, Counsel at Alston+Bird LLP The Spring 2012 BIO Intellectual Property Counsels’ Committee (IPCC) Conference, held in Austin, Texas, provided an excellent forum for intellectual property (IP) practitioners in the biotech industry to socialize, network, and participate in panel discussions focusing on the dynamic developments in the patent laws. The conference began for the general participants over margaritas and Tex-Mex fare, where attendees were already discussing recent Supreme Court and Federal Circuit decisions Read More >
Congressional Hearing on International Patent Issues: BIO Submits Comments
The House Judiciary Committee conducted a hearing on World IP Day on “International Patent Issues: Promoting a Level Playing Field for American Industry Abroad.” BIO submitted written comments for the record highlighting the unique patenting challenges that biotechnology companies face around the world. “To fully understand what is needed to level the playing field for the biotechnology sector in international markets, one must understand the intellectual property (IP) needs of the biotechnology sector. Biotechnology innovation Read More >
BIO Convention 2012: Biotech IP and Tech Transfer Sessions
Recent court decisions and ongoing implementation of the America Invents Act are certain to impact the life sciences industry. The 2012 BIO International Convention will feature an educational track devoted to Biotech Patenting and Tech Transfer to discuss legal and legislative developments and how they are likely to impact biotech companies. This year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA. Recent Developments Read More >
New Patented Drugs Save Us All Money and Help Those in Dire Need
New patented drugs actually save the United States and its citizens lots of money. In fact, new drugs save 7 times more in non-drug spending than they cost. Those savings come as new drugs result in reduced hospital and nursing home admissions which far exceed the cost of using newer drugs. New patented prescription drugs can also reduce the need for expensive surgeries and hospital stays. This data clearly articulates that the cost of treating Read More >
